Head to head
TransMedics vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: TMDX · ABT
TMDX
TransMedics
85.25-9.33%
1-year price shape — -31% over the period
Quant Rating E · 11/100
vs
ABT
Abbott Laboratories
103.00-0.84%
1-year price shape — -15% over the period
Quant Rating D · 22/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories has the highest Quant Rating (22); Abbott Laboratories has done best over the past year (-15%); Abbott Laboratories pays the highest dividend yield.
| TMDX | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 85.25 | 103.00 |
| Change today | -9.33% | -0.84% |
| 1-year return | -31.2% | -15.4% |
| Market cap | $2.96B | $178.39B |
| 52-week range | 60.11 – 156.00 | 80.89 – 126.70 |
| Valuation | ||
| P/E (TTM) | 23.23 | 38.29 |
| P/E percentile, own 5-yr range | 67th | 99th |
| P/B | 5.38 | 3.50 |
| Dividend yield | 0.00% | 2.41% |
| Profitability & growth | ||
| EPS (TTM) | 4.87 | 3.72 |
| Net profit (TTM) | $169.15M | $6.44B |
| Revenue (TTM) | $727.65M | $48.23B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +41.1% | +14.5% |
| Gross margin | 58.6% | 56.9% |
| Operating margin | 11.9% | 13.8% |
| Net margin | 19.9% | 9.7% |
| Free cash flow (TTM) | $44.70M | $6.76B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 103.7% | 81.2% |
| Insider activity (12mo) | 30 buy / 19 sell | 36 buy / 12 sell |
| Short interest (% of float) | 25.6% | 1.1% |
| Analyst consensus | 78% buy / 22% hold (9) | 93% buy / 7% hold (15) |
| Analyst price target | $105 (+23%) | $122 (+18%) |
| StockVane view | ||
| StockVane Quant Rating | E (11) | D (22) |
| Company | ||
| Employees | 898 | 115,000 |
| Founded | 1998 | 1900 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.